<DOC>
	<DOCNO>NCT01868906</DOCNO>
	<brief_summary>The aim study ass , 18F-FMISO PET , hypoxia high grade glioma change spinal cord stimulation subset patient . Additionally , potential correlation pathological , image clinical parameter analyze .</brief_summary>
	<brief_title>FMISO-PET Brain Tumors SCS Effect</brief_title>
	<detailed_description>Tumour ischaemia-hypoxia decrease efficacy radio-chemotherapy . Polarographic probe ( 18F-FMISO-PET ) study demonstrate prognostic value . Additionally hypoxia modification may increase survival . However , high grade glioma ( HGG ) well establish method evaluate modify tumor hypoxia . We previously describe spinal cord stimulation ( SCS ) modify oxygenation , blood flow metabolism malignant glioma . The aim study ass 18F-FMISO PET : hypoxia HGG change spinal cord stimulation subset patient . Additionally , potential correlation pathological , image clinical parameter analyze . 18F-FMISO PET perform 20 patient diagnosis HGG : surgery/biopsy radical treatment 3D radiotherapy temozolomide . A subset 10 patient undergo two study 18F- FMISO-PET ( one SCS `` '' one SCS `` '' ) . In patient , SCS connect 1 hour 1 hour radiotherapy session , day-time day adjuvant temozolomide . 18F-FMISO PET result take account patient management . Patients follow least end adjuvant temozolomide ( 6 month end concurrent radiochemotherapy ) .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>Patients pathologically confirm ( first presentation relapse ) high grade glioma ( Grade III Grade IV accord WHO criterion ) propose radical treatment 3D radiotherapy temozolomide . Patients 1875 year old . Karnofsky &gt; = 60 % ECOG = &lt; 2 . Signed informed consent . Clinical psychological contraindication fly ( 18FFMISOPET realize Madrid ) SCSplacement ( subset ) . Pregnant breastfeed woman woman fertile age use safe contraceptive method intend use one trial . Safe contraceptive method oral parenteral contraceptive treatment barrier method : masculine feminine condom , diaphragm and/or intrauterine device ( IUD ) withdrawal course study . Serious coexist concurrent illness , include follow : uncontrolled severe infection , heart , liver kidney disease Lung thromboembolism . Another malignancy last 5 year basal cell squamous cell carcinoma skin carcinoma situ cervix . Patients life expectancy &lt; 3 month . Patients follow : creatinine &gt; 2 mg/dl , neutrophils &lt; 1.5 * 10^9/L , platelet &lt; 100 * 10^9/L hemoglobin &lt; 8.5 g/dL . Contraindications receive radiotherapy chemotherapy Clinical psychological contraindication placement spinal cord stimulation device ( specific subset patient ) . Patients unable unwilling meet protocol study . Patients meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Brain Tumors</keyword>
	<keyword>Cancer Imaging</keyword>
	<keyword>Fluoromisonidazole</keyword>
	<keyword>FMISO PET</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>High Grade Glioma</keyword>
	<keyword>Hypoxia Modification</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Radiation-Sensitizing Agents</keyword>
	<keyword>Spinal Cord Stimulation</keyword>
	<keyword>Tumor Hypoxia Measurement</keyword>
</DOC>